Megan Kruse, MD, of Cleveland Clinic

Articles

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Ongoing Research Efforts in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.

AE Management With Neratinib in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.

Unmet Needs in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.

Evolving and Current Standards of Care for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

Prognosis and Survival Outcomes for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

Unmet Needs and Clinical Pearls in the Treatment of HER2+ mBC

July 20th 2023

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

Ongoing Research in HER2+ Metastatic Breast Cancer

July 13th 2023

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

HER2CLIMB-02: Tucatinib and T-DM1 in HER2+ Breast Cancer

July 13th 2023

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

Treating HER2+ Breast Cancer with CNS Involvement

July 6th 2023

Clinical insights on approaches to treating HER2+ metastatic breast cancer with central nervous system involvement.

Updates from ASCO 2023 in HER2+ Metastatic Breast Cancer

July 6th 2023

Megan Kruse, MD, reviews clinical trial data updates from the 2023 ASCO Annual Meeting on HER2+ metastatic breast cancer.

Data Updates from SABCS 2022 in HER2+ Metastatic Breast Cancer

June 29th 2023

An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.

Evolving Treatment Strategies for HER2+ Metastatic Breast Cancer

June 29th 2023

Megan Kruse, MD, discusses the evolving treatment landscape for patients with HER2+ metastatic breast cancer.

Dr. Kruse on the Effect of Socioeconomic Disparities on Survival Outcomes in Breast Cancer

January 5th 2023

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

Dr. Kruse on the Effects of the MAINTAIN Trial on HR+/HER2- Breast Cancer Treatment

October 11th 2022

Megan Kruse, MD, discusses the real-world effects of the phase 2 MAINTAIN trial on treatment in advanced hormone receptor–positive, HER2-negative breast cancer.

Dr. Kruse on the Results of a Study Comparing Outcomes in Pleomorphic Vs Non-Pleomorphic Invasive Lobular Carcinoma

December 10th 2021

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Dr. Kruse on How to Converse About Biosimilars in Breast Cancer

December 18th 2019

Megan Kruse, MD, discusses how to converse with patients with breast cancer about implementing biosimilars in treatment.